Multicenter, Open-label Clinical Study of PD-L1/CTLA4 BsAb Combined With Chemotherapy in Locally Advanced and Metastatic Pancreatic Cancer
Latest Information Update: 04 Sep 2023
At a glance
- Drugs Erfonrilimab (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Gemcitabine (Primary) ; Irinotecan (Primary) ; Oxaliplatin (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 31 Aug 2023 Planned primary completion date changed from 1 Nov 2022 to 1 Nov 2023.
- 07 Jun 2022 Results (As of Jan 10, 2022, n=21 )presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 20 Jul 2021 New trial record